Generic Livdelzi Availability
Last updated on May 7, 2025.
Livdelzi is a brand name of seladelpar, approved by the FDA in the following formulation(s):
LIVDELZI (seladelpar lysine - capsule;oral)
-
Manufacturer: GILEAD SCIENCES INC
Approval date: August 14, 2024
Strength(s): EQ 10MG BASE [RLD]
Is there a generic version of Livdelzi available?
No. There is currently no therapeutically equivalent version of Livdelzi available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Livdelzi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Treatment of intrahepatic cholestatic diseases
Patent 10,272,058
Issued: April 30, 2019
Inventor(s): Boudes Pol & McWherter Charles A.
Assignee(s): CymaBay Therapeutics, Inc.Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.
Patent expiration dates:
- March 19, 2035✓
- March 19, 2035
-
Treatment of intrahepatic cholestatic diseases
Patent 11,406,611
Issued: August 9, 2022
Inventor(s): Boudes; Pol et al.
Assignee(s): CymaBay Therapeutics, Inc. (Newark, CA)Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt.
Patent expiration dates:
- March 19, 2035✓
- March 19, 2035
-
Treatment of intrahepatic cholestatic diseases
Patent 11,596,614
Issued: March 7, 2023
Inventor(s): Boudes; Pol et al.
Assignee(s): CymaBay Therapeutics, Inc. (Dana Point, CA)Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.
Patent expiration dates:
- March 19, 2035✓
- March 19, 2035
-
4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
Patent 7,301,050
Issued: November 27, 2007
Inventor(s): Kuo; Gee-Hong et al.
Assignee(s): Janssen Pharmaceutical N.V. (Beerse, BE)The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.
Patent expiration dates:
- August 2, 2025✓✓
- August 2, 2025
-
Lysine salts of 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives
Patent 7,709,682
Issued: May 4, 2010
Inventor(s): Abdel-Magid; Ahmed F. et al.
Assignee(s): Janssen Pharmaceutica N.V. (Beerse, BE)The present invention is directed to a novel lysine salts, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by PPAR delta. The present invention is further directed to a novel process for the preparation of said lysine salts.
Patent expiration dates:
- September 13, 2026✓
- September 13, 2026
-
Treatment of intrahepatic cholestatic diseases
Patent 9,486,428
Issued: November 8, 2016
Inventor(s): Boudes Pol & McWherter Charles A.
Assignee(s): CymaBay Therapeutics, Inc.Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt.
Patent expiration dates:
- March 19, 2035✓
- March 19, 2035
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- August 14, 2029 - NEW CHEMICAL ENTITY
- August 14, 2031 - TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN ADULTS WHO HAVE HAD AN INADEQUATE RESPONSE TO URSODEOXYCHOLIC ACID (UDCA), OR IN PATIENTS UNABLE TO TOLERATE UDCA
More about Livdelzi (seladelpar)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- FDA approval history
- Drug class: miscellaneous metabolic agents
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
